Publisher: Consultant Live

Anaphylaxis recognition criteria have not been updated to reflect infant-specific presentations, even as newer international definitions already incorporate them.

Reframing when caregivers reach for epinephrine and expanding stock epinephrine access could meaningfully reduce delayed treatment in infants and toddlers with anaphylaxis, according to Jay Lieberman, MD, professor at the University of Tennessee Health Science Center and program director of the Allergy/Immunology Fellowship Program at Le Bonheur Children’s Hospital.

New reviews outline barriers to epinephrine use and support age-specific anaphylaxis recognition criteria in infants and toddlers, says Jay Lieberman, MD.

At RAD2026, Lieberman notes advances in immunology and systemic therapies that are reshaping the link between dermatology and allergy/immunology.

New accelerated TMS protocols and an FDA-approved at-home device are changing how psychiatrists treat MDD after antidepressant failure.

February 2026 brought several notable developments across allergy and immunology, spanning regulatory decisions, updated clinical guidance, and emerging research presented at the 2026 American Academy of Allergy, Asthma, & Immunology annual meeting in Philadelphia from February 27 to March 2.

Part 4 highlights how expanding epinephrine delivery options can reduce barriers, support earlier administration, and improve real-world anaphylaxis outcomes. Jay Lieberman, MD, is an associate professor from the College of Medicine in Memphis, department of pediatrics, and division of pediatric pulmonology at the University of Tennessee Health Science Center.

Investigative topical immunomodulator ILYX-002 has proven its efficacy in treating moderate-to-severe dry eye disease (DED) by achieving its primary endpoint of total conjunctival staining in the recent ILYX-002-201 phase 2 trial.